Enfusion, Inc. (ENFN)
Total Valuation
Enfusion has a market cap or net worth of $811.28 million. The enterprise value is $747.73 million.
| Market Cap | 811.28M |
| Enterprise Value | 747.73M |
Important Dates
The next earnings date is Thursday, March 23, 2023, after market close.
| Estimated Earnings Date | Mar 23, 2023 |
| Ex-Dividend Date | n/a |
Share Statistics
Enfusion has 68.99 million shares outstanding. The number of shares has decreased by -24.68% in one year.
| Shares Outstanding | 68.99M |
| Shares Change (YoY) | -24.68% |
| Shares Change (QoQ) | +55.78% |
| Owned by Insiders (%) | 4.65% |
| Owned by Institutions (%) | 108.00% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 67.11 |
| PS Ratio | 5.73 |
| Forward PS | 4.19 |
| PB Ratio | 13.27 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.28 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.01
| Current Ratio | 8.01 |
| Quick Ratio | 7.72 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
Financial Efficiency
Return on equity (ROE) is -309.20% and return on invested capital (ROIC) is -447.60%.
| Return on Equity (ROE) | -309.20% |
| Return on Assets (ROA) | -163.10% |
| Return on Capital (ROIC) | -447.60% |
| Revenue Per Employee | $158,840 |
| Profits Per Employee | -$199,683 |
| Employee Count | 892 |
| Asset Turnover | 1.30 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Enfusion has paid $531,000 in taxes.
| Income Tax | 531,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -2.89% in the last 52 weeks.
| Beta (1Y) | n/a |
| 52-Week Price Change | -2.89% |
| 50-Day Moving Average | 10.70 |
| 200-Day Moving Average | 11.49 |
| Average Volume (30 Days) | 320,354 |
Short Selling Information
The latest short interest is 1.86 million, so 2.70% of the outstanding shares have been sold short.
| Short Interest | 1.86M |
| Short Previous Month | 1.66M |
| Short % of Shares Out | 2.70% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.70 |
Income Statement
In the last 12 months, Enfusion had revenue of $141.69 million and -$178.12 million in losses. Loss per share was -$3.05.
| Revenue | 141.69M |
| Gross Profit | 97.72M |
| Operating Income | -305.83M |
| Pretax Income | -177.59M |
| Net Income | -178.12M |
| EBITDA | -171.30M |
| EBIT | -177.27M |
| Loss Per Share | -$3.05 |
Balance Sheet
| Cash & Cash Equivalents | 63.54M |
| Total Debt | n/a |
| Net Cash | 63.54M |
| Net Cash Per Share | $0.92 |
| Equity / Book Value | 61.13M |
| Book Value Per Share | 0.89 |
| Working Capital | 84.04M |
Cash Flow
In the last 12 months, operating cash flow was $823,000 and capital expenditures -$7.83 million, giving a free cash flow of -$7.00 million.
| Operating Cash Flow | 823,000 |
| Capital Expenditures | -7.83M |
| Free Cash Flow | -7.00M |
| FCF Per Share | -$0.08 |
Margins
Gross margin is 68.97%, with operating and profit margins of -215.85% and -125.71%.
| Gross Margin | 68.97% |
| Operating Margin | -215.85% |
| Pretax Margin | -125.34% |
| Profit Margin | -125.71% |
| EBITDA Margin | -120.90% |
| EBIT Margin | -125.11% |
| FCF Margin | -4.94% |
Dividends & Yields
Enfusion does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Earnings Yield | -21.96% |
| FCF Yield | -0.86% |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 24.68% |
| Shareholder Yield | 24.68% |
Analyst Forecast
The average price target for Enfusion is $13.06, which is 11.05% higher than the current price. The consensus rating is "Buy".
| Price Target | $13.06 |
| Price Target Difference | 11.05% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |